Skip to main content
. Author manuscript; available in PMC: 2017 Nov 13.
Published in final edited form as: Leukemia. 2017 May 10;31(12):2661–2669. doi: 10.1038/leu.2017.141

Figure 2.

Figure 2

Silencing of KDM6B reduces MM cell growth.

(a,b) MM cell lines were transduced with shRNA targeting KDM6B (shKDM6B) or control shRNA targeting luciferase (shLuc). Three days post infection (two days post puromycin selection) is designated as day 0. (a) On day 0, whole cell lysates were extracted and subjected to immunoblot analysis with the indicated antibodies. (b) Cell viability was determined by MTT assay on days 0 and 5. The cell growth rate (day 5/day 0) relative to shLuc is shown.

(c) MM.1S and RPMI 8226 cells expressing Cas9 were transduced with sgRNA against KDM6B (sgKDM6B) or control sgRNA against EGFP (sgEGFP). Three days post infection is designated as day 0. On day 0, whole cell lysates were extracted and subjected to immunoblot analysis with the indicated antibodies (left panel). FLAG-tagged Cas9 was detected by anti-FLAG. Cell growth rate (day 5/day 0) relative to sgEGFP is shown (right panel).

(b,c) Data represent mean ± s.d. of quadruplicate cultures. ***P < 0.001 compared with control.